ELTX
Elicio Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Price History
Fundamentals
| Market Cap | $98.10M |
| P/E Ratio (TTM) | - |
| Forward P/E | -1.95 |
| EPS (TTM) | $-2.36 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -1076.34% |
| Debt/Equity | - |
| Recommendation | Strong Buy 1.5 |
| Analyst Target | $20.67 |
| Analysts | 3 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 25.1 |
| Beta | 1.44 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $16.00 |
| 52-Week Low | $2.66 |
| 50-Day Avg | $9.65 |
| 200-Day Avg | $9.65 |
| Avg Volume | $1.45M |
| Volume | $2.36M |
Performance Analysis
BULLISHELTX shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:07 UTC
Back to Screener Export Report